153 related articles for article (PubMed ID: 38244089)
1. Follow-up of vascular-targeted photodynamic therapy in a real-world setting.
Borkowetz A; Kwe J; Boehm K; Baunacke M; Herout R; Lucke M; Burcea A; Thomas C
World J Urol; 2024 Jan; 42(1):55. PubMed ID: 38244089
[TBL] [Abstract][Full Text] [Related]
2. Vascular-targeted Photodynamic Therapy in Unilateral Low-risk Prostate Cancer in Germany: 2-yr Single-centre Experience in a Real-world Setting Compared with Radical Prostatectomy.
Flegar L; Buerk B; Proschmann R; Propping S; Groeben C; Baunacke M; Herout R; Huber J; Thomas C; Borkowetz A
Eur Urol Focus; 2022 Jan; 8(1):121-127. PubMed ID: 33602642
[TBL] [Abstract][Full Text] [Related]
3. Medium-term Follow-up of Vascular-targeted Photodynamic Therapy of Localized Prostate Cancer Using TOOKAD Soluble WST-11 (Phase II Trials).
Noweski A; Roosen A; Lebdai S; Barret E; Emberton M; Benzaghou F; Apfelbeck M; Gaillac B; Gratzke C; Stief C; Azzouzi AR
Eur Urol Focus; 2019 Nov; 5(6):1022-1028. PubMed ID: 29661587
[TBL] [Abstract][Full Text] [Related]
4. TOOKAD(®) Soluble vascular-targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer.
Azzouzi AR; Barret E; Moore CM; Villers A; Allen C; Scherz A; Muir G; de Wildt M; Barber NJ; Lebdai S; Emberton M
BJU Int; 2013 Oct; 112(6):766-74. PubMed ID: 24028764
[TBL] [Abstract][Full Text] [Related]
5. Feasibility, safety, and efficacy of salvage radical prostatectomy after Tookad® Soluble focal treatment for localized prostate cancer.
Lebdai S; Villers A; Barret E; Nedelcu C; Bigot P; Azzouzi AR
World J Urol; 2015 Jul; 33(7):965-71. PubMed ID: 25614256
[TBL] [Abstract][Full Text] [Related]
6. Determination of optimal drug dose and light dose index to achieve minimally invasive focal ablation of localised prostate cancer using WST11-vascular-targeted photodynamic (VTP) therapy.
Moore CM; Azzouzi AR; Barret E; Villers A; Muir GH; Barber NJ; Bott S; Trachtenberg J; Arumainayagam N; Gaillac B; Allen C; Schertz A; Emberton M
BJU Int; 2015 Dec; 116(6):888-96. PubMed ID: 24841929
[TBL] [Abstract][Full Text] [Related]
7. Tumour irradiation combined with vascular-targeted photodynamic therapy enhances antitumour effects in pre-clinical prostate cancer.
Sjoberg HT; Philippou Y; Magnussen AL; Tullis IDC; Bridges E; Chatrian A; Lefebvre J; Tam KH; Murphy EA; Rittscher J; Preise D; Agemy L; Yechezkel T; Smart SC; Kinchesh P; Gilchrist S; Allen DP; Scheiblin DA; Lockett SJ; Wink DA; Lamb AD; Mills IG; Harris A; Muschel RJ; Vojnovic B; Scherz A; Hamdy FC; Bryant RJ
Br J Cancer; 2021 Aug; 125(4):534-546. PubMed ID: 34155340
[TBL] [Abstract][Full Text] [Related]
8. [Vascular targeted photodynamic therapy in low-risk prostate cancer. A literature review].
Kleinclauss F; Frontczak A; Balssa L; Lebdai S; Azzouzi R
Prog Urol; 2019; 29(8-9):393-401. PubMed ID: 31266699
[TBL] [Abstract][Full Text] [Related]
9. Median 4-year outcomes of salvage irreversible electroporation for localized radio-recurrent prostate cancer.
Geboers B; Scheltema MJ; Blazevski A; Katelaris A; Doan P; Ali I; Agrawal S; Barreto D; Matthews J; Haynes AM; Delprado W; Shnier R; Thompson JE; Stricker PD
BJU Int; 2023 Jun; 131 Suppl 4():14-22. PubMed ID: 36594205
[TBL] [Abstract][Full Text] [Related]
10. Decision Regret and Quality of Life after Focal Therapy with Vascular-Targeted Photodynamic Therapy (TOOKAD®) for Localized Prostate Cancer.
Flegar L; Baunacke M; Buerk BT; Proschmann R; Zacharis A; Propping S; Huber J; Thomas C; Borkowetz A
Urol Int; 2022; 106(9):903-908. PubMed ID: 34814157
[TBL] [Abstract][Full Text] [Related]
11. Current evidence for focal laser ablation and vascular-targeted photodynamic therapy for localized prostate cancer: review of literature published in the last 2 years.
Candela L; Kasraeian A; Barret E
Curr Opin Urol; 2022 Mar; 32(2):192-198. PubMed ID: 35013079
[TBL] [Abstract][Full Text] [Related]
12. Erectile function after WST11 vascular-targeted photodynamic therapy for low-risk prostate cancer treatment.
Chelly S; Maulaz P; Bigot P; Azzouzi AR; Lebdai S
Asian J Androl; 2020; 22(5):454-458. PubMed ID: 31939351
[TBL] [Abstract][Full Text] [Related]
13. [Functional and oncological outcome of salvage prostatectomy of locally recurrent prostate cancer following radiation therapy].
Heidenreich A; Ohlmann C; Ozgür E; Engelmann U
Urologe A; 2006 Apr; 45(4):474-81. PubMed ID: 16465521
[TBL] [Abstract][Full Text] [Related]
14. Comparing High-Intensity Focal Ultrasound Hemiablation to Robotic Radical Prostatectomy in the Management of Unilateral Prostate Cancer: A Matched-Pair Analysis.
Albisinni S; Aoun F; Bellucci S; Biaou I; Limani K; Hawaux E; Peltier A; van Velthoven R
J Endourol; 2017 Jan; 31(1):14-19. PubMed ID: 27799004
[TBL] [Abstract][Full Text] [Related]
15. Focal High-intensity Focused Ultrasound Targeted Hemiablation for Unilateral Prostate Cancer: A Prospective Evaluation of Oncologic and Functional Outcomes.
Feijoo ER; Sivaraman A; Barret E; Sanchez-Salas R; Galiano M; Rozet F; Prapotnich D; Cathala N; Mombet A; Cathelineau X
Eur Urol; 2016 Feb; 69(2):214-20. PubMed ID: 26164416
[TBL] [Abstract][Full Text] [Related]
16. Positron Emission Tomography/Computed Tomography with Gallium-68-labeled Prostate-specific Membrane Antigen Detects Relapse After Vascular-targeted Photodynamic Therapy in a Prostate Cancer Model.
Alvim R; Nagar K; Das S; Lebdai S; Wong N; Somma A; Hughes C; Thomas J; Monette S; Scherz A; Kim K; Grimm J; Coleman JA
Eur Urol Focus; 2021 Mar; 7(2):472-478. PubMed ID: 31227464
[TBL] [Abstract][Full Text] [Related]
17. Focal cryoablation: a treatment option for unilateral low-risk prostate cancer.
Durand M; Barret E; Galiano M; Rozet F; Sanchez-Salas R; Ahallal Y; Macek P; Gaya JM; Cerruti J; Devilliers H; Loeffler J; Amiel J; Vallancien G; Cathelineau X
BJU Int; 2014 Jan; 113(1):56-64. PubMed ID: 24053685
[TBL] [Abstract][Full Text] [Related]
18. Vascular-targeted photodynamic therapy (padoporfin, WST09) for recurrent prostate cancer after failure of external beam radiotherapy: a study of escalating light doses.
Trachtenberg J; Weersink RA; Davidson SR; Haider MA; Bogaards A; Gertner MR; Evans A; Scherz A; Savard J; Chin JL; Wilson BC; Elhilali M
BJU Int; 2008 Aug; 102(5):556-62. PubMed ID: 18494829
[TBL] [Abstract][Full Text] [Related]
19. Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study.
Ahmed HU; Hindley RG; Dickinson L; Freeman A; Kirkham AP; Sahu M; Scott R; Allen C; Van der Meulen J; Emberton M
Lancet Oncol; 2012 Jun; 13(6):622-32. PubMed ID: 22512844
[TBL] [Abstract][Full Text] [Related]
20. Oncological and Quality-of-life Outcomes Following Focal Irreversible Electroporation as Primary Treatment for Localised Prostate Cancer: A Biopsy-monitored Prospective Cohort.
Blazevski A; Scheltema MJ; Yuen B; Masand N; Nguyen TV; Delprado W; Shnier R; Haynes AM; Cusick T; Thompson J; Stricker P
Eur Urol Oncol; 2020 Jun; 3(3):283-290. PubMed ID: 31103721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]